drugset
drugset / Trial / NCT05249621

A Randomized Phase 1 of of MZE001 in Healthy Volunteers

NCT05249621 ↗

Phase 1 Completed 121 enrolled Maze Therapeutics
RandomizedSequentialTriple-blindTreatment

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single (SAD) / multiple (MAD) ascending dose and food effect study.

Timeline

Start
2022-02-07
Primary completion
2022-12-21
Completion
2022-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject MZE001 Small molecule — Oral

Indications

No indication recorded.